Veracyte Accounts Payable vs Retained Earnings Analysis
VCYT Stock | USD 20.63 0.51 2.53% |
Veracyte financial indicator trend analysis is much more than just breaking down Veracyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Veracyte is a good investment. Please check the relationship between Veracyte Accounts Payable and its Retained Earnings accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
Accounts Payable vs Retained Earnings
Accounts Payable vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Veracyte Accounts Payable account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.
The correlation between Veracyte's Accounts Payable and Retained Earnings is -0.75. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Veracyte, assuming nothing else is changed. The correlation between historical values of Veracyte's Accounts Payable and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Veracyte are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Accounts Payable i.e., Veracyte's Accounts Payable and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.75 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Accounts Payable
An accounting item on the balance sheet that represents Veracyte obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Veracyte are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Veracyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Veracyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.At this time, Veracyte's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 392.7 K in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 227.0M | 236.0M | 235.2M | 247.0M | Cost Of Revenue | 74.4M | 101.6M | 137.9M | 144.8M |
Veracyte fundamental ratios Correlations
Click cells to compare fundamentals
Veracyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Veracyte fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 275.2M | 457.2M | 1.2B | 1.2B | 1.1B | 1.2B | |
Other Current Liab | 13.7M | 11.7M | 42.4M | 44.0M | 41.2M | 43.2M | |
Total Current Liabilities | 17.5M | 16.8M | 64.2M | 62.6M | 61.2M | 64.3M | |
Total Stockholder Equity | 239.5M | 421.2M | 1.1B | 1.1B | 1.0B | 1.1B | |
Other Liab | 6.1M | 8.4M | 13.1M | 7.6M | 8.7M | 5.6M | |
Property Plant And Equipment Net | 17.7M | 16.8M | 31.1M | 30.9M | 30.9M | 32.4M | |
Net Debt | (145.7M) | (337.0M) | (154.3M) | (139.5M) | (203.8M) | (193.6M) | |
Retained Earnings | (246.7M) | (281.6M) | (357.2M) | (393.7M) | (468.1M) | (444.7M) | |
Accounts Payable | 2.3M | 3.1M | 12.4M | 11.9M | 12.9M | 13.6M | |
Cash | 159.3M | 349.4M | 173.2M | 154.2M | 216.5M | 117.7M | |
Non Current Assets Total | 87.5M | 81.5M | 944.7M | 907.8M | 852.2M | 894.8M | |
Non Currrent Assets Other | 2.0M | 2.0M | (35.1M) | (26.8M) | 6.0M | 6.3M | |
Other Assets | 2.0M | 9.8M | 2.9M | 6.2M | 1.0 | 0.95 | |
Cash And Short Term Investments | 159.3M | 349.4M | 173.2M | 178.9M | 216.5M | 119.7M | |
Net Receivables | 19.3M | 18.5M | 41.5M | 44.0M | 45.1M | 47.3M | |
Common Stock Total Equity | 50K | 58K | 71K | 72K | 82.8K | 86.9K | |
Common Stock Shares Outstanding | 46.1M | 53.2M | 67.9M | 71.5M | 72.6M | 41.6M | |
Liabilities And Stockholders Equity | 275.2M | 457.2M | 1.2B | 1.2B | 1.1B | 1.2B | |
Non Current Liabilities Total | 18.3M | 19.2M | 27.2M | 18.6M | 32.5M | 19.6M | |
Inventory | 6.8M | 4.7M | 11.2M | 14.3M | 16.1M | 16.9M | |
Other Current Assets | 2.2M | 3.2M | 17.2M | 11.5M | 8.0M | 4.6M | |
Other Stockholder Equity | 486.1M | 702.8M | 1.5B | 1.5B | 1.5B | 1.6B | |
Total Liab | 35.8M | 35.9M | 91.3M | 81.2M | 93.7M | 98.4M | |
Property Plant And Equipment Gross | 17.7M | 9.0M | 31.1M | 30.9M | 63.7M | 66.9M | |
Total Current Assets | 187.7M | 375.7M | 243.1M | 248.6M | 285.6M | 148.7M | |
Accumulated Other Comprehensive Income | (12.0M) | 0.0 | (15.1M) | (31.3M) | (24.0M) | (22.8M) | |
Common Stock | 50K | 58K | 71K | 72K | 73K | 42.9K | |
Property Plant Equipment | 8.9M | 9.0M | 31.1M | 30.9M | 35.5M | 37.3M | |
Short Long Term Debt Total | 13.6M | 12.3M | 18.9M | 14.7M | 12.6M | 16.3M | |
Net Tangible Assets | 171.7M | 358.6M | 185.9M | 379.3M | 436.2M | 458.0M | |
Long Term Debt | 25.2M | 23.9M | 694K | 810K | 931.5K | 884.9K | |
Retained Earnings Total Equity | (246.7M) | (281.6M) | (357.2M) | (393.7M) | (354.3M) | (372.1M) | |
Long Term Debt Total | 25.2M | 23.9M | 694K | 810K | 931.5K | 884.9K | |
Capital Surpluse | 486.1M | 702.8M | 1.5B | 1.5B | 1.7B | 1.8B | |
Deferred Long Term Liab | 4.2M | 3.9M | 5.6M | 4.5M | 5.2M | 4.3M | |
Intangible Assets | 65.0M | 59.9M | 202.7M | 174.9M | 88.6M | 66.2M | |
Short Term Debt | 1.4M | 1.6M | 4.8M | 4.1M | 5.1M | 6.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Veracyte Stock analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 5.123 | Quarterly Revenue Growth 0.175 | Return On Assets (0.01) | Return On Equity (0.06) |
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.